RE: Full Case Study Document AVA61038 Feb 2025 11:43
Feet on the ground, the valuation is contained within the recent Peel note, signed off by the company. Whilst I believe valuation and justifications are somewhat muted, they remain closer to reality.
We go off RNS/ company validated information that the company sign off.
AVA6103 is multiple years away from development in human. Is it now the focus because of we assume it’ll sell soon? If so, certainly not for the numbers quoted here.